PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24380047-2	2013	The aim of this preclinical study was to compare [(18)F]fluorothymidine ([(18)F]FLT) PET to [(18)F]FDG PET regarding early metabolic changes of sarcoma in the course of targeted cancer therapy.	alovudine	56-71	thyroid stimulating hormone receptor	Mus musculus	85-88	
12839975-1	2003	3"-Deoxy-3"-[(18)F]fluorothymidine ([(18)F]FLT) has been proposed as a new marker for imaging tumor proliferation by positron emission tomography (PET).	alovudine	0-34	thyroid stimulating hormone receptor	Mus musculus	147-150	
25323103-0	2015	Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3"-Deoxy-3"-[18F]-fluorothymidine PET.	alovudine	78-111	thyroid stimulating hormone receptor	Mus musculus	112-115	
16885362-2	2006	We assessed whether 3"-deoxy-3"-[(18)F]fluorothymidine-positron emission tomography ([18F]FLT-PET) could be used to noninvasively measure the biological activity of a novel HDACI LAQ824 in vivo.	alovudine	20-54	thyroid stimulating hormone receptor	Mus musculus	94-97	
15899811-1	2005	We have assessed the potential of [18F]fluorothymidine positron emission tomography ([18F]FLT-PET) to measure early cytostasis and cytotoxicity induced by cisplatin treatment of radiation-induced fibrosarcoma 1 (RIF-1) tumor-bearing mice.	alovudine	39-54	thyroid stimulating hormone receptor	Mus musculus	94-97	
15632041-0	2005	Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3"-deoxy-3"-18F-fluorothymidine PET.	alovudine	80-111	thyroid stimulating hormone receptor	Mus musculus	112-115